AI-generated analysis. Always verify with the original filing.
Aprea Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, with Q4 net loss of $2.5 million ($0.32 per basic share) and full year net loss of $12.6 million ($1.93 per basic share), alongside early clinical proof-of-concept for APR-1051 showing two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer patients. Cash and equivalents stood at $14.6 million as of December 31, 2025, sufficient into Q1 2027 with recent private placement proceeds.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac
Other Events. On March 16, 2026, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release issued by Aprea Therapeutics, Inc. dated March 1
| Metric | Value | Basis |
|---|---|---|
| Operating Loss | $2.60 | GAAP |
| Net Loss | $2.50 | GAAP |
| Net Loss per Basic Share | $0.32 | GAAP |
| Operating Loss | $13.20 | GAAP |
| Grant Revenues | $0.30 | GAAP |
| Net Loss | $12.60 | GAAP |
| Net Loss per Basic Share | $1.93 | GAAP |
Eugene (Gene) Kennedy, MD
Effective: 2026-02